Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma

Benjamin Miron, Daniel M. Geynisman

Research output: Contribution to journalEditorial

5 Scopus citations
Original languageEnglish
Pages (from-to)374-376
Number of pages3
JournalEuropean Urology
Volume82
Issue number4
DOIs
StatePublished - Oct 2022

Keywords

  • Carcinoma, Transitional Cell/drug therapy
  • Humans
  • Interleukin-2
  • Nivolumab/therapeutic use
  • Urinary Bladder Neoplasms/drug therapy
  • Urologic Neoplasms/drug therapy

Fingerprint

Dive into the research topics of 'Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma'. Together they form a unique fingerprint.

Cite this